滤泡树突状细胞
生发中心
间质细胞
生物
癌症研究
树突状细胞
免疫疗法
C-C趋化因子受体7型
抗原呈递
免疫学
CCL19型
T细胞
癌症
主要组织相容性复合体
抗原
癌症免疫疗法
肿瘤微环境
CD40
细胞生物学
抗原提呈细胞
免疫系统
细胞
CD80
亲和力成熟
过继性细胞移植
淋巴结
抗体
癌细胞
CXCR5型
淋巴系统
细胞疗法
胰腺癌
作者
Raphaël Mattiuz,Jesse Boumelha,Emmanouil Aerakis,Jessica Le Bérichel,Pauline Hamon,László Halász,Abishek Balachandra Vaidya,Brian Y. Soong,Emir Radkevich,Hye Mi Kim,Matthew D. Park,Romain Donné,Leanna Troncoso,Rachel A. Kaplan,Clotilde Hennequin,Isaias Hernández-Verdín,Lucía López,Frederika Rentzeperis,Darwin D’souza,Medard Ernest
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2026-07-16
卷期号:393 (6808): eady1678-eady1678
被引量:11
标识
DOI:10.1126/science.ady1678
摘要
Tertiary lymphoid structures (TLSs) are associated with immunotherapy response, yet the mechanisms controlling their formation and maintenance remain unclear. Using spatial transcriptomics and multiplex imaging across human tumors, we found that CCR7 + mature dendritic cells (DCs) accumulate in TLSs. In a mouse non–small cell lung cancer model that forms mature TLSs, we show that early TLS development requires interferon-γ (IFN-γ)–driven type 1 conventional dendritic cell (cDC1) maturation, migration to tumor-draining lymph nodes (tdLNs), and T cell recruitment. As tumors progress, TLSs persist independently of tdLN T cell egress, coinciding with cDC1 accumulation within intratumoral CCL19 stromal hubs. There, cDC1–major histocompatibility complex class 1 (MHC-I) and –MHC-II concomitant antigen presentation, along with CD40 signaling, sustain TLS, T follicular helper (T FH ) cell pool, germinal centers, and tumor-specific immunoglobulin G (IgG). These findings highlight local mature cDC1s as key TLS orchestrators and potential targets to enhance antitumor TLS function.
科研通智能强力驱动
Strongly Powered by AbleSci AI